WO2012017166A3 - Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide - Google Patents

Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide Download PDF

Info

Publication number
WO2012017166A3
WO2012017166A3 PCT/FR2011/051742 FR2011051742W WO2012017166A3 WO 2012017166 A3 WO2012017166 A3 WO 2012017166A3 FR 2011051742 W FR2011051742 W FR 2011051742W WO 2012017166 A3 WO2012017166 A3 WO 2012017166A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
pathological condition
benzenesulfonamide
compound treatment
excessive effect
Prior art date
Application number
PCT/FR2011/051742
Other languages
English (en)
Other versions
WO2012017166A2 (fr
Inventor
Jean-François ZAGURY
Matthieu Montes
Hadley Mouhsine
Hélène GUILLEMAIN
Original Assignee
Vaxconsulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxconsulting filed Critical Vaxconsulting
Priority to CA2805206A priority Critical patent/CA2805206A1/fr
Priority to US13/811,144 priority patent/US8975399B2/en
Priority to EP11754705.9A priority patent/EP2595620A2/fr
Publication of WO2012017166A2 publication Critical patent/WO2012017166A2/fr
Publication of WO2012017166A3 publication Critical patent/WO2012017166A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/20—Acenaphthenes; Hydrogenated acenaphthenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ou l'un de ses sels d'addition avec les acides pharmaceutiquement acceptables, pour son utilisation dans une méthode de traitement d'une pathologie lie un effet excessif du TNF-alpha et pour son utilisation dans une méthode de traitement du corps humain ou animal comme inhibiteur direct du TNF alpha.
PCT/FR2011/051742 2010-07-19 2011-07-19 Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide WO2012017166A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2805206A CA2805206A1 (fr) 2010-07-19 2011-07-19 Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US13/811,144 US8975399B2 (en) 2010-07-19 2011-07-19 Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF
EP11754705.9A EP2595620A2 (fr) 2010-07-19 2011-07-19 Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1055867 2010-07-19
FR1055867A FR2962649A1 (fr) 2010-07-19 2010-07-19 Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US201161443132P 2011-02-15 2011-02-15
US61/443,132 2011-02-15

Publications (2)

Publication Number Publication Date
WO2012017166A2 WO2012017166A2 (fr) 2012-02-09
WO2012017166A3 true WO2012017166A3 (fr) 2012-07-19

Family

ID=43566620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2011/051742 WO2012017166A2 (fr) 2010-07-19 2011-07-19 Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide

Country Status (5)

Country Link
US (1) US8975399B2 (fr)
EP (1) EP2595620A2 (fr)
CA (1) CA2805206A1 (fr)
FR (1) FR2962649A1 (fr)
WO (1) WO2012017166A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491956A (zh) 2010-09-13 2014-01-01 麦克罗拜奥提斯公司 病毒进入哺乳动物细胞的抑制剂
ES2796850T3 (es) * 2013-07-18 2020-11-30 Baylor College Medicine Composiciones para la prevención de una reacción alérgica
US10112933B2 (en) 2013-07-18 2018-10-30 Baylor College Of Medicine Methods and compositions for treatment of fibrosis
EP3021841B1 (fr) 2013-07-18 2022-11-16 Baylor College Of Medicine Méthodes et compositions de traitement de l'atrophie musculaire, de la faiblesse musculaire, et/ou de la cachexie
WO2015130947A1 (fr) * 2014-02-26 2015-09-03 Howard University Utilisation de dérivés benzène-sulfonamides comme inhibiteurs de l'intégrase du vih
WO2016073897A1 (fr) 2014-11-06 2016-05-12 Northwestern University Inhibition de la motilité de cellules cancéreuses
CA2990477A1 (fr) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Derives de phenylsulfonamido-benzofurane et leurs utilisations dans le traitement de maladies proliferatives
CN105085450A (zh) * 2015-09-14 2015-11-25 中国药科大学 苯并呋喃类衍生物、其制备方法及其治疗作用
WO2018086531A1 (fr) * 2016-11-08 2018-05-17 正大天晴药业集团股份有限公司 Composé de sulfonamides en tant qu'inhibiteur d'adnccc
US10494334B2 (en) * 2018-03-28 2019-12-03 Academia Sinica Compounds to inhibit calcium/calmodulin dependent protein kinase II and applications thereof
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
EP3773537B1 (fr) 2018-04-19 2022-03-23 Tvardi Therapeutics, Inc. Inhibiteurs de stat3
CN111067889B (zh) * 2019-11-15 2022-11-18 徐州医科大学 2-甲基萘并[1,2-b]呋喃类化合物在制备与糖尿病肾病有关药物方面的应用
CN113004222B (zh) * 2019-12-19 2022-11-18 复旦大学 一种氨基二硫代过酸硫酯类化合物及其制备方法和应用
EP4093377A1 (fr) 2020-01-24 2022-11-30 Tvardi Therapeutics, Inc. Composés thérapeutiques, formulations et leurs utilisations
WO2021150912A1 (fr) * 2020-01-24 2021-07-29 Tvardi Therapeutics, Inc. Composés thérapeutiques, formulations et leurs utilisations
WO2022243574A1 (fr) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibiteurs de slc16a3 à base de 3-(phtalazin-1-yl) benzènesulfonamide et leur utilisation thérapeutique

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (fr) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited Inhibiteurs de phosphodiesterase d'amp cyclique et du facteur de necrose tumorale
WO1996014317A1 (fr) * 1994-11-07 1996-05-17 J. Uriach & Cia. S.A. Nouveaux derives piperidines a activite antagoniste du facteur paf
WO1998016503A2 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Preparation d'acides ortho-sulfonamido-aryl hydroxamiques et leur utilisation comme metalloproteinases matricielles ou inhibiteurs de tace
WO1998033768A1 (fr) * 1997-02-03 1998-08-06 Pfizer Products Inc. Derives d'acide arylsulfonylaminohydroxamique
WO1999026616A1 (fr) * 1997-11-25 1999-06-03 Warner-Lambert Company Inhibiteurs benzenesulfamides de la phosphodiesterase iv et utilisation therapeutique de ces derniers
WO2000040576A2 (fr) * 1999-01-07 2000-07-13 Fujisawa Pharmaceutical Co., Ltd. Compose cyclique
WO2001047875A1 (fr) * 1999-12-27 2001-07-05 Ortho-Mcneil Pharmaceutical, Inc. Derives d'aminoalkylamide substitues utilises en tant qu'antagonistes de l'hormone folliculostimulante
US6294539B1 (en) * 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
US20020120137A1 (en) * 2000-09-05 2002-08-29 Tularik Inc. FXR modulators
WO2003026651A1 (fr) * 2001-09-28 2003-04-03 Indevus Pharmaceuticals, Inc. Methode d'inhibition de la production et/ou des effets des cytokines proinflammatoires intestinales, des prostaglandines et autres
WO2004054974A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Antagonistes de ccr5 utiles comme agents therapeutiques
WO2004089415A2 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
WO2004089470A2 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique d'amides substitues
EP0758021B1 (fr) * 1995-08-07 2006-03-29 POLIFARMA S.p.A. Méthode pour déterminer l'activité thérapeutique des inhibiteurs de métalloprotéinase, nouveaux composés inhibiteurs, et leur application thérapeutique
WO2007092681A2 (fr) * 2006-01-27 2007-08-16 Bristol-Myers Squibb Company Derives de piperidinyl en tant que modulateurs de l'activite du recepteur de chimiokine
WO2007116374A1 (fr) * 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Nouveaux composés sulfonamides
WO2007121124A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
US20090093415A1 (en) * 2005-04-21 2009-04-09 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
US20090118292A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US20090186920A1 (en) * 2008-01-21 2009-07-23 Henner Knust Sulfonamides as orexin antagonists
WO2009133294A2 (fr) * 2008-04-09 2009-11-05 Centre National De La Recherche Scientifique Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
WO2010003023A2 (fr) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Inhibiteurs d'héparane sulfate
WO2010125831A1 (fr) * 2009-05-01 2010-11-04 Raqualia Pharma Inc. Dérivés d'acide sulfamoyl benzoïque en tant qu'antagonistes de trpm8

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312358B2 (en) 2000-10-17 2007-12-25 Laboratoires Serono Sa Pharmaceutically active sulfanilide derivatives
US7960435B2 (en) * 2006-12-15 2011-06-14 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
WO2009086303A2 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2299999B1 (fr) * 2008-06-04 2017-08-16 Baylor College Of Medicine Inhibiteurs de stat3

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (fr) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited Inhibiteurs de phosphodiesterase d'amp cyclique et du facteur de necrose tumorale
WO1996014317A1 (fr) * 1994-11-07 1996-05-17 J. Uriach & Cia. S.A. Nouveaux derives piperidines a activite antagoniste du facteur paf
EP0758021B1 (fr) * 1995-08-07 2006-03-29 POLIFARMA S.p.A. Méthode pour déterminer l'activité thérapeutique des inhibiteurs de métalloprotéinase, nouveaux composés inhibiteurs, et leur application thérapeutique
WO1998016503A2 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Preparation d'acides ortho-sulfonamido-aryl hydroxamiques et leur utilisation comme metalloproteinases matricielles ou inhibiteurs de tace
WO1998033768A1 (fr) * 1997-02-03 1998-08-06 Pfizer Products Inc. Derives d'acide arylsulfonylaminohydroxamique
WO1999026616A1 (fr) * 1997-11-25 1999-06-03 Warner-Lambert Company Inhibiteurs benzenesulfamides de la phosphodiesterase iv et utilisation therapeutique de ces derniers
WO2000040576A2 (fr) * 1999-01-07 2000-07-13 Fujisawa Pharmaceutical Co., Ltd. Compose cyclique
US6294539B1 (en) * 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
WO2001047875A1 (fr) * 1999-12-27 2001-07-05 Ortho-Mcneil Pharmaceutical, Inc. Derives d'aminoalkylamide substitues utilises en tant qu'antagonistes de l'hormone folliculostimulante
US20020120137A1 (en) * 2000-09-05 2002-08-29 Tularik Inc. FXR modulators
WO2003026651A1 (fr) * 2001-09-28 2003-04-03 Indevus Pharmaceuticals, Inc. Methode d'inhibition de la production et/ou des effets des cytokines proinflammatoires intestinales, des prostaglandines et autres
WO2004054974A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Antagonistes de ccr5 utiles comme agents therapeutiques
WO2004089470A2 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique d'amides substitues
WO2004089415A2 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
US20090093415A1 (en) * 2005-04-21 2009-04-09 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
WO2007092681A2 (fr) * 2006-01-27 2007-08-16 Bristol-Myers Squibb Company Derives de piperidinyl en tant que modulateurs de l'activite du recepteur de chimiokine
WO2007116374A1 (fr) * 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Nouveaux composés sulfonamides
WO2007121124A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
US20090118292A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US20090186920A1 (en) * 2008-01-21 2009-07-23 Henner Knust Sulfonamides as orexin antagonists
WO2009133294A2 (fr) * 2008-04-09 2009-11-05 Centre National De La Recherche Scientifique Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
WO2010003023A2 (fr) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Inhibiteurs d'héparane sulfate
WO2010125831A1 (fr) * 2009-05-01 2010-11-04 Raqualia Pharma Inc. Dérivés d'acide sulfamoyl benzoïque en tant qu'antagonistes de trpm8

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AL-MASOUDI NAJIM A ET AL: "Nitroimidazoles Part 6. Synthesis, structure and in vitro anti-HIV activity of new 5-substituted piperazinyl-4-nitroimidazole derivatives", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 18, no. 4, 2007, pages 191 - 200, XP008149758, ISSN: 0956-3202 *

Also Published As

Publication number Publication date
US8975399B2 (en) 2015-03-10
EP2595620A2 (fr) 2013-05-29
CA2805206A1 (fr) 2012-02-09
FR2962649A1 (fr) 2012-01-20
US20130123266A1 (en) 2013-05-16
WO2012017166A2 (fr) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012017166A3 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
PL2753343T3 (pl) Kompozycja zawierająca n-acetylocysteinę oraz bakterie probiotyczne zdolne do przywrócenia własnego działania barierowego żołądka, które zostaje zniszczone podczas leczenia nadkwaśności soku żołądkowego inhibitorami pompy protonowej
WO2011123719A3 (fr) Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PT2768312E (pt) Composição para utilização na promoção de crescimento ósseo saudável e/ou na prevenção e/ou tratamento de doença óssea
WO2012023623A3 (fr) Agent pour le traitement du syndrome de hunter
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2012047951A3 (fr) Cellules souches pulmonaires humaines et leurs utilisations
EP4272839A3 (fr) Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
WO2013116753A8 (fr) Acides gras comme agents anti-inflammatoires
WO2012071369A3 (fr) Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
AU2012265069A1 (en) Compression bandage for placing on the human or animal body
IL191908A0 (en) Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
WO2013045270A3 (fr) Compositions antitranspirantes et procédé pour diminuer la transpiration
WO2017011356A3 (fr) Procédés et compositions pour traiter des maladies et des états induits par des médicaments
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
WO2011138785A3 (fr) Utilisation thérapeutique de ccl1
AU2011343331A8 (en) Compositions based on clay and bee pollen, method for preparing same, and nutritional and therapeutic uses thereof
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
EP2488507A4 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
EP2278981A4 (fr) Marqueurs biologiques, réponse au traitement contre la douleur, l inflammation et les lésions neuronales ou vasculaires, et procédés d utilisation afférents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11754705

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2805206

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13811144

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011754705

Country of ref document: EP